The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 15, 2014
Filed:
Jul. 05, 2011
Maria Eliana Lanio Ruiz, La Habana, CU;
Luis Enrique Fernández Molina, La Habana, CU;
Rady Judith Laboroe Quintana, La Habana, CU;
Yoelys Cruz Leal, La Habana, CU;
Maria Del Carmen Luzardo Lorenzo, La Habana, CU;
Circe Mesa Pardillo, La Habana, CU;
Carlos Manuel Alvarez Valcárcel, La Habana, CU;
Isabel Fabiola Pazos Santos, La Habana, CU;
Mayra Tejuca Martínez, La Habana, CU;
Aisel Valle Garay, La Habana, CU;
Maria Eugenia Alonso Biosca, La Habana, CU;
Liem Canet Santos, La Habana, CU;
Maria Eliana Lanio Ruiz, La Habana, CU;
Luis Enrique Fernández Molina, La Habana, CU;
Rady Judith Laboroe Quintana, La Habana, CU;
Yoelys Cruz Leal, La Habana, CU;
Maria del Carmen Luzardo Lorenzo, La Habana, CU;
Circe Mesa Pardillo, La Habana, CU;
Carlos Manuel Alvarez Valcárcel, La Habana, CU;
Isabel Fabiola Pazos Santos, La Habana, CU;
Mayra Tejuca Martínez, La Habana, CU;
Aisel Valle Garay, La Habana, CU;
Maria Eugenia Alonso Biosca, La Habana, CU;
Liem Canet Santos, La Habana, CU;
Centro De Immunologia Molecular, La Habana, CU;
Abstract
The present invention relates to the field of biotechnology applied to human health. The invention describes a vaccine vehicle which toxins from eukaryotic organisms are encapsulated in liposomes with multiple lipid layers, obtained by means of the process of dehydration/rehydration, the lipid composition of which is dipalmitoylphosphatidylcholine:cholesterol in a molar ration of 1:1, which are designed for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. The compositions described allow modulation of the specific CTL immune response to one or more antigens co-encapsulated in the liposomes that containing the toxin. The vaccine vehicle of the present invention presents advantages as compared with others described in the prior art owning to the robust and functional nature of the immune response induced and also the immunomodulating properties thereof.